SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction — A Win against a Formidable Foe
Volume: 385, Issue: 16, Pages: 1522 - 1524
Published: Oct 14, 2021
Abstract
Mark Drazner comments on the findings of the EMPEROR-Preserved trial, which assessed the potential benefit of empagliflozin in patients with a preserved EF. He notes that the findings represent a major win against a medical condition that had previously proved...
Paper Details
Title
SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction — A Win against a Formidable Foe
Published Date
Oct 14, 2021
Volume
385
Issue
16
Pages
1522 - 1524
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History